Bipolar disorder drugs and treatment sales will expand through 2036, with mood stabilizers holding a 34.0% share of the product segment in 2026. The market is expected to reach USD 4.7 billion in 2026 and USD 6.0 billion by 2036, creating an absolute opportunity of USD 1.3 billion.